Clinical Trial Update: Abemaciclib + Pembrolizumab In Glioblastoma [Phase 2]

View source ↗

Summary

Clinical trial NCT04118036 studying Abemaciclib plus Pembrolizumab in glioblastoma has been withdrawn (Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• VERZENIO (ABEMACICLIB)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Glioblastoma | Phase 2 | Status: WITHDRAWN